Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.95 |
| ▸ | HPGD | P15428 | 6/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.95 |
| ▸ | CA12 | O43570 | 2/20 | 0.95 |
| ▸ | CA1 | P00915 | 2/20 | 0.95 |
| ▸ | CA2 | P00918 | 2/20 | 0.95 |
| ▸ | CA7 | P43166 | 2/20 | 0.95 |
| ▸ | CA9 | Q16790 | 2/20 | 0.95 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.95 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.95 |
| ▸ | CA4 | P22748 | 1/20 | 0.95 |
| ▸ | CA6 | P23280 | 1/20 | 0.95 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.95 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | G6PD | P11413 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL27878551 | 1.00 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL28120594 | 1.00 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL9391879 | 0.97 | ALDH1A1 (0.90) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL8160376 | 0.97 | ALDH1A1 (0.90) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL28334086 | 0.97 | ALDH1A1 (0.90) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29606432 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29362663 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29360246 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL17156443 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1509155 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115806554-B | Preparation and application of colon targeting prodrug and drug delivery system thereof | 沈阳海诺威医药科技有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-115806554-A | Preparation and application of colon-targeted prodrug and drug delivery system thereof | 沈阳海诺威医药科技有限公司 | 2023-03-17 | — | — | CN | claimed |
| EP-3416938-A1 | ALKOXYLATED HYDROXYBENZOIC ACID ESTERS OR AMIDES | Clariant International Ltd (CH) | 2018-12-26 | — | — | EP | claimed |
| CN-107417563-A | A kind of method that Doxycycline Hyclate is reclaimed in the refinement mother liquor from Doxycycline Hyclate | 扬州联博药业有限公司 | 2017-12-01 | — | — | CN | claimed |
| WO-2017140510-A1 | ALKOXYLATED HYDROXYBENZOIC ACID ESTERS OR AMIDES | CLARIANT INTERNATIONAL LTD (CH) | 2017-08-24 | — | — | WO | claimed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| CN-222931014-U | Centrifugal device for recovering 5-chlorosalicylic acid solvent | 南通罗森化工有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-118632699-A | Prevention or treatment of cardiovascular disease with high penetration prodrugs of aspirin and other non-steroidal anti-inflammatory drugs | 苏州泰飞尔医药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| CN-111808011-B | High penetration composition and its application | 泰飞尔生物医药(苏州)有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-1226465-A2 | TINTED LENSES AND METHODS OF MANUFACTURE | Doshi, Praful (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020030788-A1 | Tinted lenses and methods of manufacture | DOSHI PRAFUL (US) | 2002-03-14 | — | — | US | disclosed |
| US-6315410-B1 | Tinted lenses and methods of manufacture | DOSHI, PRAFUL | 2001-11-13 | — | — | US | disclosed |
| WO-2001040846-A2 | TINTED LENSES AND METHODS OF MANUFACTURE | DOSHI PRAFUL (US) | 2001-06-07 | — | — | WO | disclosed |
| CN-1166831-A | Novel benzyl pyrimidines | HOFFMANN LA ROCHE (CH) | 1997-12-03 | — | — | CN | disclosed |
| US-4900748-A | Carbamates related to (-)-physostigmine as cholinergic agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1990-02-13 | — | — | US | disclosed |
| US-4388246-A | THERMAL SPLITTING OF CARBAMATES | BAYER AKTIENGESELLSCHAFT (DE) | 1983-06-14 | — | — | US | disclosed |
| US-4168248-A | CONTAINING A METHYL NONANOL OR NONENOL OR ITS CARBOXYLIC ESTER | FRITZSCHE DODGE & OLCOTT INC. (US) | 1979-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ALDH1A1 1724/4885KDM4E 3941/4885HPGD 30/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ALDH1A1 1724/4885KDM4E 3941/4885HPGD 30/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | ALDH1A1 2330/4885KDM4E 671/4885HPGD 4761/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ALDH1A1 1724/4885KDM4E 3941/4885HPGD 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.